IRVINE, CA: Allergan has selected GCI Health to support the launch of Botox for the preventative treatment of headaches, which was approved by the FDA on October 15 for use in adults with chronic migraines.
Caroline Van Hove, VP, corporate communications for Allergan, told PRWeek the agency won the account following a competitive review.
“The agencies we looked at all needed to have substantial expertise in the headache and migraine area as well as women's health issues,” said Van Hove.
She declined to disclose the other agencies considered, but said GCI Health demonstrated the most expertise. Allergan continues to work with Chandler Chicco Agency on Botox Cosmetic and a number of other PR firms for different products. Van Hove also declined to name the other agencies.
Working on the account from its New York and West Coast offices, GCI Health will help “raise awareness around chronic migraine as a disease,” said Van Hove. She said they'll also aim to raise awareness around “proper diagnosis, symptom recognition, and the proper referral pathways.”
GCI Health has started work on the account, including around the FDA approval for the indication.
“We're passionate about the opportunity and look forward to shining a light on chronic migraine and the impact on patients, which despite affecting millions of Americans, is grossly under-diagnosed,” said Wendy Lund, CEO at GCI Health.